Stack · Skin / cosmetic
GHK-Cu + BPC-157 + TB-500 + KPV (“KLOW”)
Marketed as an extended “GLOW” blend with KPV added for its proposed anti-inflammatory activity. Four unapproved compounds are being combined on the basis of separate laboratory mechanisms, not a combination study. Constituent lists vary between sellers.
Compounds
- GHK-Cu
Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine
No FDA-approved product
- BPC-157
Synthetic 15-residue peptide corresponding to a partial sequence of human gastric juice protein BPC
No FDA-approved product
- TB-500
Synthetic acetylated heptapeptide corresponding to the actin-binding region of thymosin beta-4 (residues 17–23)
No FDA-approved product
- KPV
Tripeptide corresponding to the C-terminal sequence of α-melanocyte-stimulating hormone
No FDA-approved product
Why people combine them
Marketed as an extended “GLOW” blend with KPV added for its proposed anti-inflammatory activity. Four unapproved compounds are being combined on the basis of separate laboratory mechanisms, not a combination study. Constituent lists vary between sellers.
Therapept evaluates multi-peptide combinations like GHK-Cu + BPC-157 + TB-500 + KPV (“KLOW”) by analyzing whether the biological pathways operate independently, competitively, or synergistically, comparing preclinical hypotheses against documented human trials.
Evidence for the combination
This pairing rests entirely on community practice. No published study and no registered trial of the combination is indexed by Therapept.
Evidence for each component
- GHK-Cu — Cosmetic copper peptide with laboratory extracellular-matrix research; no approved drug product.
- BPC-157 — Animal and cell evidence plus one small retrospective human series; no completed Phase 3 trial indexed.
- TB-500 — No human interventional evidence for the fragment itself is indexed.
- KPV — Laboratory anti-inflammatory signalling data; FDA stated it had not identified human exposure data at its compounding review.
Commonly reported dosing and protocols
Displayed source by source. Therapept does not compose these into a recommended protocol.
Potential overlap and concerns
- No published study evaluates this four-component combination. Combination-specific human evidence does not exist in the sources reviewed here.
- BPC-157 and TB-500 are WADA-prohibited. KPV and GHK-Cu are not named on the 2026 list.
- Combining four unapproved substances multiplies the unknowns: impurity load, aggregation, immunogenicity and any interaction are uncharacterised.
- HHS's October 2026 enforcement-discretion policy requires a single active ingredient per compounded product. A four-peptide blend is outside that policy's conditions.
What is known
- Every component has a separate, limited evidence file.
- The combination itself has not been studied in humans or animals in any source indexed here.
What is speculative
- The claim that four compounds produce a broader or better effect than one.
- Any ratio, dose, cycle or administration schedule.
- The implication that a community name confers a defined formulation.
Sources
Last reviewed 17 September 2026 · Compiled by Therapept Editorial · How these records are built